Analysts say these two penny stocks will develop rapidly
Wall Street has mixed views on low-priced stocks. These stocks are trading at less than US$5 per share, either to attract them to attract investors with high return potential, or to send them to the mountains, but why? When we talk about high return potential, we are not exaggerating. Cheaper price points allow investors to snap up more shares when buying other, more well-known stocks. More importantly, even a trivial stock price increase can be converted into a huge percentage increase, which means that it makes sense for some investors to be cautious about penny stocks. The risks brought by these factors deter the faint-hearted, because very real problems such as weak fundamentals or unfavorable headwinds may be masked by low stock prices. So, how should investors make potential penny stock investments? By getting inspiration from the analyst community. These experts bring to the table the in-depth knowledge and rich experience of the industries they cover. With this in mind, we used TipRanks̵
7; database to find two compelling penny stocks. Both stocks have strong buy consensus ratings and huge upside potential. Matinas BioPharma (MTNB) By using its lipid nanocrystal platform (LNC) delivery technology, Matinas BioPharma hopes to solve the complex challenges related to oral small molecules, gene therapy, vaccines, proteins and peptides. Five-star analyst Robert Hazlett (Robert Hazlett) wrote for BTIG that MAT2203 is a key component of its bullish view, and its current stock price is $0.87, which is an attractive entry point. The therapy is designed as a liposomal nanocrystal (LNC) version of the broad-spectrum antifungal amphotericin B, which can be taken orally. The Phase 2 EnACT trial evaluated cryptococcal meningitis drug candidates and added the second group of recipients. The participant Hazlett pointed out that this will be “the first of many potential indications for the new antifungal drug.” Hazlett further explained his optimistic view of the therapy, “The independent DSMB unanimously recommended that it be transferred to EnACT’s second Group of patients, this is a validation event of MAT2203, because the progress of the entire cohort was evaluated by CSF fungal clearance and fungal-free count rebound rate. Therefore, the progress through the EnACT cohort indicates the activity of MAT2203 and its successful crossing of the blood-brain barrier (BBB ) In order to keep the number of fungi in the CSF reduced.” The ENHANCE-IT application for comparing MAT9001 with Amarin’s Vascepa has been completed. MAT9001 is a free fatty acid formula of MTNB’s EPA and DPA. According to Hazlett, the blood concentration of EPA produced by it is much higher than Vascepa. If this is not enough, the company recently announced a collaboration with NIAID to study liposome nanocrystals. (LNC) Gilead’s remdesivir preparation for oral oral COVID-19 therapy. Hazlett commented: “We believe this cooperation will further validate Matinas’ LNC technology.” According to his optimistic stance, Hazlett rated MTNB as “Buy”, and his $5 target price means that within the next 12 months There is an amazing upside of 474%. (To watch Hazlett’s track record, click here.) Now moving to other places on Wall Street, other analysts are responding to Hazlett’s views. Since only Buy recommendations have been issued in the past three months, MTNB has won the consensus of Strong Buy analysts. With an average price target of $4, the stock price may surge 359% from current levels. (See MTNB stock analysis on TipRanks) Equillium (EQ) leverages its in-depth understanding of immunology and its role in disease, Equillium is developing innovative treatments for severe autoimmune and inflammatory diseases. Given that the stock price is $4.25, some analysts believe it is time to trigger the trigger. After the company’s “Analyst Day” highlighted its clinical plans for the anti-CD6 monoclonal antibody itolizumab, Leerink analyst Thomas Smith remains optimistic about its long-term growth prospects. During the event, EQ released individual patient responses and biomarker analysis. Following the recent positive data from the first three studies in the 1b EQUATE phase, EQ studied the study of itolizumab in acute graft-versus-host disease (aGVHD). Looking to the future, the company hopes to expand the dose in cohort 2 and cohort 3 by recruiting three more patients in each cohort, and hopes to obtain the highest results of the trial during 1H21. Research shows that from the initial data of the 1b EQUATE stage, Smith believes that it has a rapid, profound and long-lasting response to itolizumab in aGVHD. As for the updated data, by day 57, the overall response rate (ORR) of all doses reached 80%, and 8 out of 10 patients achieved complete remission (CR). In addition, the therapy is also related to the ability to reduce the patient’s systemic steroid use and dose reduction. These results are consistent with the biomarker data, indicating that Etolizumab can rapidly reduce CD6 expression on CD4 and CD8 T cells. We believe these results are convincing and support the EQ plan to extend the dose to more GVHD patients with 0.8mg/kg and 1.6mg/kg doses. Smith explained. If this is not enough, EQ will provide preclinical and translational research to support the phase 1b EQUALIZE 1b clinical trial of itolizumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN). Smith expects the highest SLE Revenue will appear in 1Q21, and LN’s mid-term results will appear in 2H21. For this reason, Smith has rated EQ as a buy and a target price of $18. If this goal is achieved next year, investors may get about 328% of the return. (To watch Smith’s track record, click here) What do the rest of Wall Street have to say? 3 buys, no holds or sells add up to a “strong buy” consensus rating. Given the average of $15 Price target, the stock may soar by 328% in the coming year. (See EQ stock analysis on TipRanks) For a good idea to find attractively priced low-priced stocks, please visit TipRanks’ Best Buys to Buy, this is a new launch A tool that combines all the stock insights of TipRanks. Disclaimer: The views expressed in this article are limited to those unique analysts. The content is for reference only. It is very important to conduct your own analysis before making any investment.